EFFICACY AND SAFETY OF SWITCHING FROM ADALIMUMAB TO SARILUMAB IN AN OPEN-LABEL EXTENSION OF A PHASE 3 MONOTHERAPY TRIAL IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS (RA)

被引：0

作者：

Burmester, G. R. ^{[1
,2
,3
]}

Fiore, S. ^{[4
]}

Hu, C-C ^{[4
]}

van Hoogstraten, H. ^{[4
]}

Lee, Bong E. ^{[5
]}

Genovese, M. C. ^{[6
]}

机构：

[1] Charite Univ Med Berlin, Berlin, Germany

[2] Free Univ, Berlin, Germany

[3] Humboldt Univ, Berlin, Germany

[4] Sanofi Genzyme, Bridgewater, MA USA

[5] Seoul Natl Univ, Coll Med, Seoul, South Korea

[6] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA

来源：

INTERNAL MEDICINE JOURNAL | 2018年 / 48卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P33

引用

页码：21 / 21

页数：1

共 50 条

[1] Efficacy and Safety of Switching from Adalimumab to Sarilumab in an Open-Label Extension of a Phase 3 Monotherapy Trial in Patients with Active Rheumatoid Arthritis
Burmester, Gerd R.
Fiore, Stefano
Hu, Chih-Chi
Fay, Jonathan
Lee, Eun Bong
Genovese, Mark C.
ARTHRITIS & RHEUMATOLOGY, 2017, 69
[2] Efficacy and Safety of Switching from Adalimumab to Sarilumab in an Open-label Extension of a Phase 3 Monotherapy Trial in Patients with Active Rheumatoid Arthritis
Burmester, Gerd
Fiore, Stefano
Hu, Chih-Chi
Fay, Jonathan
Lee, Eun-Bong
Genovese, Mark
JOURNAL OF RHEUMATOLOGY, 2018, 45 (07) : 1035 - 1035
[3] EFFICACY AND SAFETY OF SWITCHING FROM ADALIMUMAB TO SARILUMAB IN AN OPEN-LABEL EXTENSIONOF A PHASE III MONOTHERAPY TRIAL IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS
Burrnester, Gerd R.
Fiore, Stefano
Hu, Chih-Chi
Fay, Jon
Lee, Eun Bong
Genovese, Mark C.
RHEUMATOLOGY, 2018, 57
[4] Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH openlabel extension
Burmester, Gerd R.
Strand, Vibeke
Rubbert-Roth, Andrea
Amital, Howard
Raskina, Tatiana
Gomez-Centeno, Antonio
Pena-Rossi, Claudia
Gervitz, Leon
Thangavelu, Karthinathan
St John, Gregory
Boklage, Susan
Genovese, Mark C.
RMD OPEN, 2019, 5 (02):
[5] EFFICACY AND SAFETY OF SARILUMAB MONOTHERAPY VERSUS ADALIMUMAB MONOTHERAPY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS IN THE PHASE 3 MONARCH STUDY, INCLUDING SUBPOPULATIONS
Burmester, G. R.
Lin, Y.
Mangan, E. K.
van Hoogstraten, H.
Kimura, T.
Vargas, J. I.
Lee, E. B.
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 849 - 849
[6] SWITCHING FROM ADALIMUMAB TO SARILUMAB IS ASSOCIATED WITH COMPARABLE EFFICACY BUT LOWER FUNCTIONAL IMPROVEMENT VERSUS CONTINUOUS SARILUMAB MONOTHERAPY THROUGH 48-WEEK OPEN-LABEL EXTENSION (OLE) OF THE PHASE 3 MONARCH TRIAL
Burmester, G. R.
St John, G.
Iglesias-Rodriguez, M.
Hu, C-C.
Raskina, T.
Amital, H.
Gomez Centeno, A.
Rubbert-Roth, A.
ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 952 - 953
[7] Patient-Reported Benefits of Sarilumab Monotherapy in Adult Patients with Active Rheumatoid Arthritis: Results from an Open-Label Extension Study
Strand, Vibeke
Reaney, Matthew
Mangan, Erin
van Hoogstraten, Hubert
Boklage, Susan
Hu, Chih-Chi
ARTHRITIS & RHEUMATOLOGY, 2018, 70
[8] SARILUMAB DOSE REDUCTION IN AN OPEN-LABEL EXTENSION STUDY IN RHEUMATOID ARTHRITIS PATIENTS
Genovese, Mark C.
Fay, Jon
Parrino, Janie
Beyer, Doris
Iglesias-Rodriguez, Melitza
Graham, Neil
Boddy, Alex
Martincova, Renata
Burmester, Gerd R.
RHEUMATOLOGY, 2017, 56 : 139 - 139
[9] Sarilumab Dose Reduction in an Open-Label Extension Study in RA Patients
Genovese, Mark C.
Fay, Jon
Parrino, Janie
Beyer, Doris
Iglesias-Rodriguez, Melitza
Graham, Neil
Boddy, Alex
Simon, J-Abraham
Martincova, Renata
Burmester, Gerd R.
ARTHRITIS & RHEUMATOLOGY, 2016, 68
[10] Safety and Efficacy of Long-term Sarilumab Treatment in Patients with Active Rheumatoid Arthritis: EXTEND and MONARCH Open Label Extension Studies
Burmester, Gerd
Strand, Vibeke
Kivitz, Alan
Hu, Chih-Chi
Wang, Sheldon
van Hoogstraten, Hubert
Tao, Ray
Fleischmann, Roy
ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3521 - 3525

← 1 2 3 4 5 →